In this episode, Paige Twenter, Assistant Editor at Becker’s Hospital Review, joins Scott Becker to discuss the latest developments in the healthcare industry. They dive into the FDA’s recent approval of Ozempic for chronic kidney disease, the soaring costs of GLP-1 medications, and the growing influence of Mark Cuban’s Cost Plus Drug Company in hospital and pharmacy supply chains.
GLP-1 Approvals, Drug Pricing Battles, and Mark Cuban’s Disruptive Moves in Healthcare with Paige Twenter
Advertisement
Advertisement
Next Up in Becker's Healthcare Podcast Episodes
-
In this episode, Airica Powell-Steed, Ed.D, MBA, RN, CSSMBB, FACHE, FAAN, IASSC – Interim Executive Vice President and Chief Operating…
-
This episode of the Becker’s Healthcare Podcast features Scott Sagehorn, Vice President and General Manager of the Smart Care Business…
-
In this episode, Dr. Prathibha Varkey, President of Mayo Clinic Health System, shares why culture and people are central to…
Join the 500,000+ healthcare executives who start their day with Becker’s
Advertisement
Comments are closed.